Advanced Search

 

Study ID Status Title Patient Level Data
207499/040 Completed A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/041 Completed A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/042 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/076 Completed A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/091 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/110 Completed A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/111 Completed A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease
207499/121 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/125 Completed A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/156 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/157 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/168 Completed A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/180 Completed An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD Study Listed on ClinicalStudyDataRequest.com
207499/181 Completed A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
208108/059 Completed A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects. Study Listed on ClinicalStudyDataRequest.com
208108/084 Completed An open study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Haemophilus influenzae type b vaccine administered at 2, 4, 6 months to healthy infants over 2 months of age as a primary vaccination course
208108/087 Completed Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com
208108-083 Completed A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information. Study Listed on ClinicalStudyDataRequest.com
208109/085 Completed A randomized, controlled, double-blind field efficacy trial of SmithKline Beecham Biologicals' inactivated hepatitis A vaccine using a recombinant DNA hepatitis B vaccine, Engerix®-B as control.
208109/127 Completed Open study of the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' inactivated hepatitis A vaccine administered to hemophiliac patients.
208109/139 Completed Evaluation of the safety and immunogenicity of a Hepatitis A Vaccine in Patients with Chronic Viral Hepatitis B and C and chronic liver disease of other etiology.
208109/141 Completed A pilot open group study to compare the immunogenicity, reactogenicity and safety of a standard course of hepatitis A vaccine in: HIV positive individuals with haemophilia, HIV negative individuals with haemophilia, HIV negative healthy adult male controls.
208109/145 Completed A study to assess the immunogenicity and reactogenicity of hepatitis A vaccine administered subcutaneously to patients with congenital coagulation disorders using a single primary dose and a booster at six months at a dose of 1440 ELU (in 1 ml) to adults and 720 ELU (in 0.5 ml) to children.
208109/166 Completed A double-blind, randomized, placebo controlled study to evaluate the safety and immunogenicity of Havrix( in subjects with human immunodeficiency virus (HIV) infection

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.